MD Anderson Cancer Center partners with GlaxoSmithKline

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD ANDERSON CANCER CENTER formed a research alliance with GlaxoSmithKline to strengthen its efforts in advancing anticancer immunotherapies.

This marks the fourth and final collaboration in a plan to partner with pharmaceutical companies as part of MD Anderson’s Moon Shots Program. GSK and MD Anderson will work to identify therapeutic approaches, evaluate patient responses in clinical trials, and develop immunotherapy drugs.

YOU MAY BE INTERESTED IN

The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login